Trial · NCT02304926
Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia
NCT02304926, Not applicable, Completed, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana; results first posted 2015-05-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia. Trials, record NCT02304926. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02304926
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia
- NCT number
- NCT02304926
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 42 participants, actual
- Lead sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- Conditions
- Dyslipidemia
- Interventions
- Simvastatin, Ezetimibe, Simvastatin + Ezetimibe
- First posted
- 2014-12-02
- Last updated
- 2018-03-08
- Results first posted
- 2015-05-21
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Total cholesterol concentration was measured by enzymatic assay |
| Primary | Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Low-density lipoprotein cholesterol (LDLc) concentration was calculated using the method of Friedewald. |
| Primary | High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | High-density lipoprotein cholesterol (HDLc) concentration was measured using a direct method |
| Primary | Triglycerides Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Triglyceride concentration were measured by enzymatic assay |
| Primary | Non-HDL Cholesterol Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Non-HDLc concentration was obtained by calculating the difference between total cholesterol and HDLc |
| Primary | Low Density Lipoprotein Size Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | LDL subfractions were separated by high-resolution polyacrylamide gel tubes using the Lipoprint® system. The LDL electrophoretic profile allows 2 patterns to be defined: pattern A or large and buoyant LDL, and pattern non-A or small and dense LDL. |
| Primary | Apolipoprotein B Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Levels of apolipoprotein B were determined by inmunonephelometry |
| Secondary | Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Levels of high-sensitive C-reactive protein (hsCRP) were analysed by a latex-enhanced inmunonephelometric assay |
| Secondary | Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Levels of proinflammatory cytokines (interleukin-6 (IL-6)) were analysed with a Luminex® 200™ system |
| Secondary | Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Levels of proinflammatory cytokines (tumor necrosis factor α (TNF-α)) were analysed with a Luminex® 200™ system |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | mg/dl | MEAN | |
| PRIMARY | Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | mg/dl | MEAN | |
| SECONDARY | Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | mg/l | MEAN | |
| SECONDARY | Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | pg/ml | MEAN | |
| SECONDARY | Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | pg/ml | MEAN | |
| PRIMARY | High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | mg/dl | MEAN | |
| PRIMARY | Triglycerides Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | mg/dl | MEDIAN | |
| SECONDARY | Mitochondrial Oxygen (O2) Consumption Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Nmol O2/min/million cells | MEAN | |
| SECONDARY | Reactive Oxygen Species (ROS) Production Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Fluorescence Units | MEAN | |
| SECONDARY | Membrane Potential Before and After Simvastatin/Ezetimibe Administration | Baseline, 4 weeks and 8 weeks | Fluorescence Units | MEAN |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 outcomesResults by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Simvastatin | Baseline | 255 | Standard Deviation 34 | mg/dl |
| Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Ezetimibe | Baseline | 253 | Standard Deviation 26 | mg/dl |
| Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Simvastatin | 4 weeks | 180 | Standard Deviation 29 | mg/dl |
| Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Ezetimibe | 4 weeks | 215 | Standard Deviation 33 | mg/dl |
| Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Simvastatin | 8 weeks | 173 | Standard Deviation 38 | mg/dl |
| Total Cholesterol Before and After Simvastatin/Ezetimibe Administration | Ezetimibe | 8 weeks | 169 | Standard Deviation 39 | mg/dl |
| Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration | Simvastatin | Baseline | 178 | Standard Deviation 26 | mg/dl |
| Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration | Ezetimibe | Baseline | 172 | Standard Deviation 29 | mg/dl |
| Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration | Simvastatin | 4 weeks | 106 | Standard Deviation 18 | mg/dl |
| Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration | Ezetimibe | 4 weeks | 138 | Standard Deviation 32 | mg/dl |
1 to 10 of 120Source ClinicalTrials.gov
See all 120 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Simvastatin | 22 | |
| Overall Study | STARTED | Ezetimibe | 20 | |
| Overall Study | COMPLETED | Simvastatin | 20 | |
| Overall Study | COMPLETED | Ezetimibe | 19 | |
| Overall Study | NOT COMPLETED | Simvastatin | 2 | |
| Overall Study | NOT COMPLETED | Ezetimibe | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adverse Events Were Not Collected | ||
| Total, all-cause mortality | |||
| Total, other adverse events | Adverse Events Were Not Collected | 0 | 39 |
| Total, other adverse events | 0 | 39 | |
| Total, serious adverse events | Adverse Events Were Not Collected | 0 | 39 |
| Total, serious adverse events | 0 | 39 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Adverse Events Were Not Collected vs None: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02304926
GET https://conductscience.org/api/trials/v1/NCT02304926/results?page=2